Abbisko Cayman Limited (HKG:2256)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
12.85
-0.25 (-1.91%)
Feb 13, 2026, 4:08 PM HKT
Market Cap8.81B +194.7%
Revenue (ttm)678.11M +24.4%
Net Income164.35M
EPS0.24
Shares Out672.36M
PE Ratio53.68
Forward PE840.46
Dividendn/a
Ex-Dividend Daten/a
Volume2,502,000
Average Volume1,783,676
Open13.10
Previous Close13.10
Day's Range12.67 - 13.43
52-Week Range4.80 - 19.78
Beta1.39
RSI43.16
Earnings DateMar 2, 2026

About Abbisko Cayman

Abbisko Cayman Limited engages in the research and development of pharmaceutical products in the People’s Republic of China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor in NDA/commercial trial for the treatment of tenosynovial giant cell tumors, as well as chronic graft versus host disease and solid tumors. It is also developing pivotal trial products comprising Mavorixafor (ABSK081), a CXCR4 modulator to treat warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome; a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 226
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2256
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements